NeoImmuneTech Names New CEO

NeoImmuneTech Inc., a clinical-stage T cell-focused biopharmaceutical company, has appointed Luke Oh, Ph.D. as President and Chief Executive Officer (CEO).
 
Having joined the company as President in January 2024, Oh succeeds Dr. Se Hwan Yang, Ph.D., as Chief Executive Officer of NeoImmuneTech, Inc. In his new role, he will lead NeoImmuneTech from its Rockville headquarters and overview all the operations in Korea.

About Dr. Luke Oh

Oh is an expert in regulatory policies and drug development, encompassing both biologics and small molecules. He brings over six years of regulatory experience at the U.S. FDA. His recent tenure at Samsung Bioepis as Vice-President in charge of Regulatory Development was marked by several successful preparations and submissions of biosimilar applications to regulatory agencies in the US, EU, UK, and Canada.
 
Before this position, Oh worked as Senior Staff Fellow at the U.S. FDA Division of Clinical Pharmacology III and Division of Inflammation and Immune Pharmacology, and he has held various roles in research and development for leading organizations such as Mallinckrodt Pharmaceuticals, Human Genome Sciences, and Vertex Pharmaceuticals. Oh has a Ph.D. in Neuroimmunology from the McGill University (Montreal, Canada).
 
Oh remarked: “It is an honor to lead NeoImmuneTech into the future, particularly as our main asset, NT-I7, a unique long-acting human IL-7, moves closer to potentially being the first approved treatment for Acute Radiation Syndrome (ARS). I am committed to advancing the work that Dr. Se Hwan Yang initiated, aligning the company on our business priorities, and stepping up this new phase of NeoImmuneTech.”

More NeoImmuneTech News

Earlier this year, NeoImmuneTech Inc. was granted Orphan Drug Designation (ODD) from the U.S. FDA for NT-I7 (efineptakin alfa) (rhIL-7-hyFc) for the treatment of pancreatic cancer.